Psychopharmacology

, Volume 94, Issue 1, pp 74–78 | Cite as

Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice

  • H. Pilch
  • W. E. Müller
Original Investigations

Abstract

Chronic treatment (2 weeks) with piracetam (500 mg/kg, once daily PO) elevatedm-cholinoceptor density in the frontal cortex of aged (18 months) female mice by about 30–40%, but had no effect onm-cholinoceptor density in the frontal cortex of young (4 weeks) mice. The effect of piracetam onm-cholinoceptor density as determined by the specific binding of tritiated QNB was not affected by concomitant daily treatment with either choline (200 mg/kg) or scopolamine (4 mg/kg). It is concluded that the effect of piracetam onm-cholinoceptor density could explain the positive effects which have been reported for combinations of cholinergic precursor treatment with piracetam on memory and other cognitive functions in aged experimental animals and patients and could also represent part of the possible mechanism of action of piracetam alone.

Key words

Piracetam Choline m-Cholinoceptor density Frontal cortex 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bartus RT, Dean RL, Sherman KA, Friedman E, Beer B (1981) Profound effect of combining choline and piracetam on memory enhancement and cholinergic functions in aged rats. Neurobiol Aging 2:3–8Google Scholar
  2. Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417Google Scholar
  3. Bering B, Müller WE (1985) Interaction of piracetam with several neurotransmitter receptors in the central nervous system. Arzneimittelforschung 35:1350–1352Google Scholar
  4. Collerton D (1986) Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19:1–28Google Scholar
  5. Davidson M, Mohs RC, Hollander E, Zemishlany Z, Powchik P, Ryan T, Davis KL (1987) Lecithin and piracetam in Alzheimer's disease. Biol Psychiatry 22:112–114Google Scholar
  6. Fontani G, Grazzi F, Meucci M (1984) Effect of piracetam plus choline treatment on hipppocampal rhythmic slow activity (RSA) and behavior in rabbits. Life Sci 35:1183–1189Google Scholar
  7. Franklin SR, Sethy VH, Tang AH (1986) Amnesia produced by intracerebroventricular injections of hemicholinium-3 in mice was prevented by pretreatment with piracetam-like compounds. Pharmacol Biochem Behav 25:925–927Google Scholar
  8. Freund G (1980) Cholinergic receptor loss in brains of aging mice. Life Sci 26:371–375Google Scholar
  9. Freund G, Brophy TR, Scott JD (1986) Membrane fluidization increases low-affinity muscarinic receptor binding in brain; changes with aging. Exp Gerontol 21:37–44Google Scholar
  10. Freund G (1984) Neurotransmitter function in relation to aging and alcoholism. In: Hartford JT, Samorajski T (eds) Alcoholism in the Elderly. Raven Press, New York, pp 65–83Google Scholar
  11. Friedman E, Sherman KA, Ferris SH, Reisberg B, Bartus RT, Schneck MK (1981) Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline levels. N Engl J Med 304:1490–1491Google Scholar
  12. Giurgea CE, Greindl M-G, Preat S (1983) Nootropic drugs and aging. Acta Psychiatr Belg 83:349–358Google Scholar
  13. Growdon JH, Corkin S, Huff FJ, Rosen TJ (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7:269–276Google Scholar
  14. Iversen LL (1986) The cholinergic hypothesis of dementia TIPS suppl. (Subtypes of muscarinic receptors II)Google Scholar
  15. Johns CA, Haroutunian V, Greenwald BS, Mohs RC, Davis BM, Kanof P, Horvath TB, Davis KL (1985) Development of cholinergic drugs for the treatment of Alzheimer's disease. Drug Dev Res 5:77–96Google Scholar
  16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275Google Scholar
  17. Pedata F, Moroni F, Pepeu GC (1984) Effect of nootropic agents on brain cholinergic mechanism. Clin Neuropharmacol [Suppl 1] 7:S 416Google Scholar
  18. Pedigo NW, Polk DM (1985) Reduced muscarinic receptor plasticity in frontal cortex of aged rats after chronic administration of cholinergic drugs. Life Sci 37:1443–1449Google Scholar
  19. Pedigo NW, Minor LD, Krumrei TN (1984) Cholinergic drug effects and brain muscarinic receptor binding in aged rats. Neurobiol Aging 5:227–233Google Scholar
  20. Pilch H, Müller WE (1987) Chronic treatment with choline or scopolamine indicates the presence of muscarinic cholinergic receptor plasticity in the frontal cortex of young but not of aged mice. J Neural Transm (in press)Google Scholar
  21. Platel A, Jalfre M, Pawelec C, Roux S, Porsolt RD (1984) Habituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processes. Pharmacol Biochem Behav 21:209–212Google Scholar
  22. Pomara N, Block R, Moore N, Rhiew HB, Berchou R, Stanley N, Gershon S (1984) Combined piracetam and cholinergic precursor treatment for primary degenerative dementia. IRCS Med Sci 12:388–389Google Scholar
  23. Pugsley TA, Shih YH, Coughenour L, Stewart SF (1983) Some neurochemical properties of pramiracetam (Cl-879), a new cognition-enhancing agent. Drug Dev Res 3:407–420Google Scholar
  24. Quirion R, Martel JC, Robitaille Y, Etienne P, Wood P, Nair NPV, Gauthier S (1986) Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci 13:503–510Google Scholar
  25. Shih YH, Pugsley TA (1985) The effects of various cognition-enhancing drugs on in vitro rat hippocampal synaptosomal sodium dependent high affinity choline uptake. Life Sci 36:2145–2152Google Scholar
  26. Smith RC, Vroulis G, Johnson R, Morgan R (1984) Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol Bull 20:542–545Google Scholar
  27. Terry RD, Katzman R (1983) Senile dementia of the Alzheimer type. Ann Neurol 14:497–506Google Scholar
  28. Trovarelli G, Gaiti A, De Medio G, Brunetti M, Porcellati G (1984) Biochemical studies on the nootropic drug oxiracetam in brain. Clin Neuropharmacol [Suppl 1] 7:S 418Google Scholar
  29. Valzelli L, Bernasconi S, Sala A (1980) Piracetam activity might differ according to the age of the recipient mouse. Int Pharmacopsychiatry 15:150–156Google Scholar
  30. Viticchi C, Gentile S, Piantanelli L (1984) Centrophenoxine-induced increase of beta-adrenoceptor density in brain cortex of old mice. Arch Gerontol Geriatr 3:77–82Google Scholar
  31. Waller SB, London ED (1983) Age-differences in choline acetyl-transferase activities and muscarinic receptor binding in brain regions of C 57 BL/6J mice. Exp Gerontol 18:419–425Google Scholar
  32. Woelk H (1979) Effects of piracetam on the incorporation of32P into the phospholipids of neurons and glial cells isolated from rabbit cerebral cortex. Pharmacopsychiatry 12:251–256Google Scholar
  33. Wood WG, Gorka C, Armbrecht HJ, Williamson LS, Strong R (1986) Fluidizing effects of centrophenoxine in vitro on brain and liver membranes from different age groups of mice. Life Sci 39:2089–2095Google Scholar
  34. Wurtman RJ, Fernstrom JD (1976) Control of brain neurotransmitter synthesis by precursor availability and nutritional state. Biochem Pharmacol 25:1691–1696Google Scholar
  35. Wurtman RJ, Magill SG, Reinstein DK (1981) Piracetam diminishes hippocampal ACh levels in rats. Life Sci 28:1091–1093Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • H. Pilch
    • 1
  • W. E. Müller
    • 1
  1. 1.Psychopharmacological LaboratoryCentral Institute of Mental HealthMannheimFederal Republic of Germany

Personalised recommendations